| Gene symbol | CD7 | Synonyms | GP40, LEU-9, TP41, Tp40 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q25.3 | dbXrefs | |
| Description | CD7 molecule | ||||
| GTO ID | GTC3032 |
| Trial ID | NCT05377827 |
| Disease | Adult T-Cell Leukemia/Lymphoma | Angioimmunoblastic T-Cell Lymphoma | Anaplastic Large Cell Lymphoma | T-Cell Prolymphocytic Leukemia | Peripheral T-Cell Lymphoma | T-Cell Non-Hodgkin's Lymphoma | Nasal Type Extranodal NK/T-Cell Lymphoma | Mycosis Fungoides | Primary Cutaneous Gamma-Delta T-Cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Sezary's Disease |
| Altered gene | CD7 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD7 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies |
| Year | 2022 |
| Country | United States |
| Company sponsor | Washington University School of Medicine |
| Other ID(s) | 22-x081 |
| Cohort 1 | |||||||||||
|
|||||||||||